Although there are currently no reports describing additional mechanisms on the inhibition of SMO-GLI in SCLC tumors, SMO antagonists, such as erismodegib and vismodegib, continue to be employed as they block cell proliferation and increase apoptosis. The gene discussed is SMO; the disease is small cell lung carcinoma.